Report by the ACNP Task Force on Response and Remission in Major Depressive Disorder
The DOI matches its Crossref record; 130 of the 132 references it cites were found in a registry or an index.
Abstract
This report summarizes recommendations from the ACNP Task Force on the conceptualization of remission and its implications for defining recovery, relapse, recurrence, and response for clinical investigators and practicing clinicians. Given the strong implications of remission for better function and a better prognosis, remission is a valid, clinically relevant end point for both practitioners and investigators. Not all depressed patients, however, will reach remission. Response is a less desirable primary outcome in trials because it depends highly on the initial (often single) baseline measure of symptom severity. It is recommended that remission be ascribed after 3 consecutive weeks during which minimal symptom status (absence of both sadness and reduced interest/pleasure along with the presence of fewer than three of the remaining seven DSM-IV-TR diagnostic criterion symptoms) is maintained. Once achieved, remission can only be lost if followed by a relapse. Recovery is ascribed after at least 4 months following the onset of remission, during which a relapse has not occurred. Recovery, once achieved, can only be lost if followed by a recurrence. Day-to-day functioning and quality of life are important secondary end points, but they were not included in the proposed definitions of response, remission, recovery, relapse, or recurrence. These recommendations suggest that symptom ratings that measure all nine criterion symptom domains to define a major depressive episode are p…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Both reports explicitly requested empirical validations of these now widely used consensus-based definitions.”
From Empirical evidence for definitions of episode, remission, recovery, relapse and recurrence in depression: a systematic review (2019) · cites this paper as Rush et al. (2006)
In the citing paper
“Not only were the specific operationalisations of the duration criteria by Frank et al. (1991) and Rush et al. (2006) not empirically supported”
From Empirical evidence for definitions of episode, remission, recovery, relapse and recurrence in depression: a systematic review (2019) · cites this paper as Rush et al. 2006
In the citing paper
“This definition of relapse is the one most commonly used in clinical studies.39”
Citations
Cites
The PHQ-9: Validity of a brief depression severity measure
Kroenke, K., Spitzer, R. L., & Williams, J. B. W. (2001) · Journal of General Internal Medicine · doi:10.1046/j.1525-1497.2001.016009606.x · Cited by 44,910
An inventory for measuring depression
BECK, A. T. (1961) · Archives of General Psychiatry · doi:10.1001/archpsyc.1961.01710120031004 · Cited by 38,032
(1992) · PubMed · Cited by 33,716
Hamilton, M. (1960) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.23.1.56 · Cited by 32,817 · cited 1×
“These reports have relied on a variety of reasonably chosen remission end points at study exit (eg, 17-item Hamilton Rating Scale for Depression p7 or p6 (HRSD17; Hamilton, 1960, 1967) or MontgomeryÄsberg Depression Rating Scale p10 (MADRS; Montgomery and Äsberg, 1979)).”
MethodThe MOS 36-ltem Short-Form Health Survey (SF-36): I. Conceptual Framework and Item Selection
Ware, J. E., & Sherbourne, C. D. (1992) · Medical Care · doi:10.1097/00005650-199206000-00002 · Cited by 30,033
A new depression scale designed to be sensitive to change
Montgomery, S. A., & Åsberg, M. (1979) · British Journal of Psychiatry · doi:10.1192/bjp.134.4.382 · Cited by 13,962
Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision (DSM-IV-TR)
American Psychiatric Association (2000) · doi:10.1176/appi.books.9780890423349 · Cited by 11,069
Cognitive Therapy for Depression: (675542012-001)
(2012) · PsycEXTRA Dataset · doi:10.1037/e675542012-001 · Cited by 9,663
Development of a Rating Scale for Primary Depressive Illness
HAMILTON, M. (1967) · British Journal of Social and Clinical Psychology · doi:10.1111/j.2044-8260.1967.tb00530.x · Cited by 8,410
Beck, A. T., Steer, R. A., & Brown, G. (2011) · PsycTESTS Dataset · doi:10.1037/t00742-000 · Cited by 7,535
Research works printed but not linked: 2
- American Psychiatric Association (2000b). Practice guideline for the treatment of patients with major depressive disorder (revision). Am J Psychiatry 157 (Suppl 4): 1–45.
- Weissman AN (1979). The dysfunctional attitude scale. A validation study. Diss Abst Int 40: 1389B–1390B.
Cited by
Items 201–300 of 697
Dunn, T. W., Vittengl, J. R., Clark, L. A., Carmody, T., Thase, M. E., & Jarrett, R. B. (2012) · Psychological Medicine · doi:10.1017/s0033291711001279 · Cited by 49
Self-citationFuller‐Thomson, E., Agbeyaka, S., LaFond, D. M., & Bern‐Klug, M. (2016) · Psychiatry Research · doi:10.1016/j.psychres.2016.04.041 · Cited by 55
“…define remission from depression as the amelioration of symptoms associated with the disorder (Frank et al., 1991,Bakish, 2001) Other literature has differentiated the term remission from recovery and proposed that recovery occurs over a longer term (Rush et al., 2006,Vittengl et al., 2014) .”
BackgroundTemperament and character influence on depression treatment outcome
Balestri, M., Porcelli, S., Souery, D., Kasper, S., Dikeos, D., Ferentinos, P., Papadimitriou, G. N., Rujescu, D., Martinotti, G., Di Nicola, M., et al. (2019) · Journal of Affective Disorders · doi:10.1016/j.jad.2019.04.031 · Cited by 49
“T Sixth, as not all mood disorder patients who fulfilled inclusion criteria for the studies included in the present work completed the TCI assessment and some patients were recruited in studies focusing on TRD, it is not possible to consider our sample as representative of the population of MDD or BD patients treated…”
BackgroundInfluentialRea, E., Rummel, J., Schmidt, T. T., Hadar, R., Heinz, A., Mathé, A. A., & Winter, C. (2014) · Brain Stimulation · doi:10.1016/j.brs.2013.09.002 · Cited by 47
“Stimulation was controlled by a computer-interfaced constant current generator (STG 4008, Multi Channel Systems GmbH, Reutlingen, Germany) set to a frequency of 130 Hz, a pulse width of 100 msec and current intensity of 300 mA.”
BackgroundMethodDepression and cardiovascular autonomic control: a matter of vagus and sex paradox
Tobaldini, E., Carandina, A., Toschi‐Dias, E., Erba, L., Furlan, L., Sgoifo, A., & Montano, N. (2020) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2020.06.029 · Cited by 50
A Critical Overview of the Pharmacologic Management of Treatment-Resistant Depression
Nierenberg, A. A., Katz, J., & Fava, M. (2007) · Psychiatric Clinics of North America · doi:10.1016/j.psc.2007.01.001 · Cited by 52
Self-citationPredicting relapse or recurrence of depression: A systematic review of prognostic models
Moriarty, A. S., Meader, N., Snell, K. I. E., Riley, R. D., Paton, L. W., Dawson, S., Hendon, J., Chew-Graham, C. A., Gilbody, S. M., Churchill, R. C., et al. (2022) · White Rose Research Online (University of Leeds, The University of Sheffield, University of York) · Cited by 44
Conway, C. R., Aaronson, S. T., Sackeïm, H. A., George, M. S., Zajecka, J., Bunker, M. T., Duffy, W. J., Stedman, M., Riva‐Posse, P., Allen, R. M., et al. (2024) · Brain stimulation · doi:10.1016/j.brs.2024.12.1191 · Cited by 56
Self-citationMerlo‐Pich, E., Alexander, R., D, M. F. M., & Goméni, R. (2010) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2010.159 · Cited by 46
Self-citationGüleç, M., Selvı, Y., Boysan, M., Aydın, A., Beşiroğlu, L., & Ağargün, M. Y. (2011) · Journal of Affective Disorders · doi:10.1016/j.jad.2011.05.056 · Cited by 45
“So, relapse can be defined as the re-appearance or aggravation of symptoms to score 18 or more on the HAMD-17 scale for at least 2 consecutive weeks in the partial or full remission process (Rush et al., 2006a).”
InfluentialHarkness, K. L., Theriault, J. E., Stewart, J. G., & Bagby, R. M. (2014) · Depression and Anxiety · doi:10.1002/da.22177 · Cited by 45
“New episodes occurring within 4 months of the beginning of followup were defined as relapses, and those occurring after 4 months were defined as recurrences.[54] The LEDS was administered at the end of follow-up to cover all stressors experienced over follow-up.”
BackgroundMethodRidout, N., O’Carroll, R. E., Dritschel, B., Christmas, D. M. B., Eljamel, S., & Matthews, K. (2007) · Neuropsychologia · doi:10.1016/j.neuropsychologia.2006.12.022 · Cited by 51
“The duration of these episodes are categorised in accordance with the guidelines set out in a recent report by a task force of the American College of Psychopharmacology ( ACNP ) concerning the definition of recovery and remission ( Rush et al , 2006 ) .”
Reporting outcomes in clinical trials for bipolar disorder: a commentary and suggestions for change
Martínez‐Arán, A., Vieta, E., Chengappa, K. R., Gershon, S., Mullen, J., & Paulsson, B. (2008) · Bipolar Disorders · doi:10.1111/j.1399-5618.2008.00611.x · Cited by 48
Kumar, A., Bunker, M. T., Aaronson, S. T., Conway, C. R., Rothschild, A. J., Mordenti, G., & Rush, A. J. (2019) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s196665 · Cited by 44
“The second challenge focuses on the maintenance of the optimal symptomatic benefit once achieved in the acute treatment phase, that is, the prevention of relapse (a return of the current episode) or recurrence (onset of a new episode).(3,4) The Sequenced Treatment Alternatives to Achieve Remission in Depression (STAR-…”
BackgroundSelf-citationHeerlein, K., De Giorgi, S., Degraeve, G., Frodl, T., Hagedoorn, W., Oliveira-Maia, A. J., Otte, C., Perez Sola, V., Rathod, S., Rosso, G., et al. (2022) · Journal of Affective Disorders · doi:10.1016/j.jad.2021.11.004 · Cited by 44
“While evidence indicates that MDD patients achieving remission have better long-term outcomes than those achieving response (Rush et al., 2006; Mendlewicz, 2008), and there is some research to suggest that these differences are reflected in the HCRU (Yrondi et al., 2020), there remains a lack of…”
BackgroundInfluentialUse of Antidepressants in Late-Life Depression
Rajji, T. K., Mulsant, B. H., Lotrich, F. E., Lokker, C., & Reynolds, C. F. (2008) · Drugs & Aging · doi:10.2165/00002512-200825100-00003 · Cited by 52
Scavone, C., di Mauro, G., Mascolo, A., Berrino, L., Rossi, F., & Capuano, A. (2019) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.00111 · Cited by 44
“…MDD Many patients with MDD fail to achieve a complete response with antidepressant medications and experience periods with residual symptom burdens (Rush et al., 2006) Recombinant Vesicular Stomatitis Virus with Envelope Glycoprotein replaced by Zaire ebolavirus (Kikwit Strain)…”
BackgroundGe, R., Downar, J., Blumberger, D. M., Daskalakis, Z. J., Lam, R. W., & Vila-Rodriguez, F. (2019) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2019.01.012 · Cited by 43
Plasma circulating cell-free mitochondrial DNA in depressive disorders
Fernström, J., Ohlsson, L., Asp, M., Lavant, E., Holck, A., Grudet, C., Westrin, Å., & Lindqvist, D. (2021) · PLoS ONE · doi:10.1371/journal.pone.0259591 · Cited by 51
Roca, M., López-Navarro, E., Monzón, S., Vives, M., García-Toro, M., García‐Campayo, J., Harrison, J., & Gili, M. (2015) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2015.07.020 · Cited by 55
Interian, A., Lewis‐Fernández, R., Gara, M. A., & Escobar, J. I. (2013) · Depression and Anxiety · doi:10.1002/da.22052 · Cited by 49
“Axis II disorders[1] Pharmacotherapy factors (medication type, dosing, continuity) have also received a great deal of attention, leading to the development of algorithmbased pharmacotherapy approaches.”
BackgroundMeasurement-Based Care for Unipolar Depression
Morris, D. W., & Trivedi, M. H. (2011) · Current Psychiatry Reports · doi:10.1007/s11920-011-0237-8 · Cited by 47
“Once the dosage has been titrated to a clinically therapeutic level (adequate response and tolerability), clinic visits and physician contact may be significantly reduced, keeping in mind that sustained remission is the goal of treatment [38].”
BackgroundSelf-citationHennings, J. M., Uhr, M., Klengel, T., Weber, P., Pütz, B., Touma, C., Czamara, D., Ising, M., Holsboer, F., & Lucae, S. (2015) · Translational Psychiatry · doi:10.1038/tp.2015.9 · Cited by 42
Rush, A. J., Trivedi, M. H., Stewart, J. W., Nierenberg, A. A., Fava, M., Kurian, B. T., Warden, D., Morris, D. W., Luther, J. F., Husain, M. M., et al. (2012) · FOCUS The Journal of Lifelong Learning in Psychiatry · doi:10.1176/appi.focus.10.4.492 · Cited by 42
Self-citationStem Cell Factor (SCF) is a putative biomarker of antidepressant response
Benedetti, F., Poletti, S., Hoogenboezem, T. A., Locatelli, C., Ambrée, O., de Wit, H., Wijkhuijs, A. J. M., Mazza, E. B., Bulgarelli, C., Vai, B., et al. (2016) · Journal of Neuroimmune Pharmacology · doi:10.1007/s11481-016-9672-y · Cited by 45
“Response to treatment was categorically defined according to the strict remission criterium of a final IDS-C score < 12 (Rush et al. 2006).”
Is treatment-resistant depression a useful concept?
Malhi, G. S., & Byrow, Y. (2016) · Evidence Based Mental Health · doi:10.1136/eb-2015-102299 · Cited by 41
“In practical terms, response is used to gauge decision-making such as when to modify antidepressant dosage, augment therapy, combine medications or substitute them altogether, and switch strategy.(10) 11 In research, response is conventionally a reduction in baseline symptomatology of 50% or more, as measured on stand…”
BackgroundClinimetric Dilemmas in Outcome Scales for Mental Disorders
Bech, P. (2016) · Psychotherapy and Psychosomatics · doi:10.1159/000448810 · Cited by 41
Reeves, G. M., Rohan, K. J., Langenberg, P., Snitker, S., & Postolache, T. T. (2012) · Journal of Affective Disorders · doi:10.1016/j.jad.2011.12.003 · Cited by 40
Personalized medicine in major depressive disorder — Opportunities and pitfalls
Miller, D. B., & O'Callaghan, J. P. (2012) · Metabolism · doi:10.1016/j.metabol.2012.08.021 · Cited by 45
“MDD is a lifelong disorder; it may be chronic or characterized by frequent recurrences with a mean of about 6 episodes in 15years [6].”
BackgroundEfficacy and Safety of Auricular Acupuncture for Depression: A Randomized Clinical Trial
Rodrigues, D. M. D. O., Menezes, P. R., Silotto, A. E. M. R., Heps, A., Sanches, N. M. P., Schveitzer, M. C., & Faisal‐Cury, A. (2023) · JAMA Network Open · doi:10.1001/jamanetworkopen.2023.45138 · Cited by 59
Mavandadi, S., Benson, A., DiFilippo, S., Streim, J. E., & Oslin, D. (2015) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2015.2157 · Cited by 39
Toward a very brief quality of life enjoyment and Satisfaction Questionnaire
Rush, A. J., South, C. C., Jha, M. K., Grannemann, B. D., & Trivedi, M. H. (2018) · Journal of Affective Disorders · doi:10.1016/j.jad.2018.08.052 · Cited by 39
Self-citationThomas, L., Abel, A., Ridgway, N., Peters, T., Kessler, D. S., Hollinghurst, S. P., Turner, K. M., Garland, A., Jerrom, B., Morrison, J., et al. (2011) · Contemporary Clinical Trials · doi:10.1016/j.cct.2011.10.016 · Cited by 43
Economic burden of relapse/recurrence in patients with major depressive disorder
Gauthier, G., Mucha, L., Shi, S., & Guerin, A. (2019) · Journal of Drug Assessment · doi:10.1080/21556660.2019.1612410 · Cited by 36
Pharmacotherapy for Depression and Anxiety in the Primary Care Setting
Parish, A. L., Gillis, B. D., & Anthamatten, A. (2023) · The Journal for Nurse Practitioners · doi:10.1016/j.nurpra.2023.104556 · Cited by 46
Motivational interviewing improves depression outcome in primary care: A cluster randomized trial.
Keeley, R. D., Brody, D. S., Engel, M. D., Burke, B. L., Nordstrom, K., Moralez, E. A., Dickinson, L. M., & Emsermann, C. B. (2016) · Journal of Consulting and Clinical Psychology · doi:10.1037/ccp0000124 · Cited by 73
Baune, B. T., & Christensen, M. C. (2019) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2019.00335 · Cited by 41
“Health care providers’ (HCPs) perceptions of treatment goals have traditionally focused on achieving full remission (6, 7) or on ameliorating mood symptoms (2), with the objective of removing depressive symptoms and reducing the risk of subsequent depressive episodes (6).”
BackgroundThe responsiveness of the different versions of the H amilton Depression Scale
Bech, P. (2015) · World Psychiatry · doi:10.1002/wps.20248 · Cited by 42
“Over the past decade, the goal when evaluating the effect of an antidepressant has been the event of remission rather than response (7).”
BackgroundZimmerman, M., Martinez, J., Attiullah, N., Friedman, M., Toba, C., & Boerescu, D. A. (2012) · Depression and Anxiety · doi:10.1002/da.21987 · Cited by 37
Memory support strategies and bundles: A pathway to improving cognitive therapy for depression?
Dong, L., Lee, J. Y., & Harvey, A. G. (2017) · Journal of Consulting and Clinical Psychology · doi:10.1037/ccp0000167 · Cited by 39
“Using American College of Neuro-Psychopharmacology (ACNP) criteria (Rush et al., 2006), response was defined as 50% change in IDS-SR from baseline to posttreatment, remission was defined as less than or equal to 14 on the IDS-SR at posttreatment, relapse was defined as greater than or equal to 26…”
MethodNovick, D., Montgomery, W. S., Vorstenbosch, E., Moneta, M. V., Dueñas, H., & Haro, J. M. (2017) · Patient Preference and Adherence · doi:10.2147/ppa.s138750 · Cited by 48
“Treatment of MDD traditionally aims to reduce depressive symptoms.(3) Consequently, the treatment is considered fully effective when complete or near-complete absence of the MDD symptoms (for a certain period of time) is achieved.”
Howland, R. H. (2009) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s5453 · Cited by 42
Agomelatine: The evidence for its place in the treatment of depression
Eser, D. (2009) · Core Evidence · doi:10.2147/ce.s6005 · Cited by 37
The STAR*D Study: A Four-Course Meal That Leaves Us Wanting More
Nelson, J. C. (2006) · American Journal of Psychiatry · doi:10.1176/ajp.2006.163.11.1864 · Cited by 43
Antidepressant Pharmacotherapy in Adults With Type 2 Diabetes
Anderson, R. J., Gott, B. M., Sayuk, G. S., Freedland, K. E., & Lustman, P. J. (2009) · Diabetes Care · doi:10.2337/dc09-1466 · Cited by 42
“This report presents a secondary analysis of acute-phase data aggregated from two previously published treatment trials of pharmacotherapy for MDD in adults with diabetes.”
BackgroundInfluentialJadoon, A., Chiu, C., McDermott, L., Cunningham, P., Frangou, S., Chang, C., Sun, I.-W., Liu, S., Lu, M., Su, K., et al. (2011) · Journal of Affective Disorders · doi:10.1016/j.jad.2011.09.007 · Cited by 40
Lukat, J., Becker, E. S., Lavallee, K. L., van der Veld, W. M., & Margraf, J. (2016) · Clinical Psychology & Psychotherapy · doi:10.1002/cpp.2026 · Cited by 41
“Remission is found to be predicted by positive mental health and better global functioning which is also in line with other studies of specific disorders (e.g., Bardone-Cone et al., 2010; Rush et al., 2006).”
ResultPrognostic models for predicting relapse or recurrence of major depressive disorder in adults
Moriarty, A. S., Meader, N., Snell, K. I., Riley, R. D., Paton, L. W., Chew-Graham, C. A., Gilbody, S., Churchill, R., Phillips, R. S., Ali, S., et al. (2021) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd013491.pub2 · Cited by 36
A quantitative review on outcome-to-antidepressants in melancholic unipolar depression
Valerio, M. P., Szmulewicz, A., & Martino, D. J. (2018) · Psychiatry Research · doi:10.1016/j.psychres.2018.03.088 · Cited by 38
Rohde, P., Silva, S. G., Tonev, S. T., Kennard, B. D., Vitiello, B., Kratochvil, C. J., Reinecke, M. A., Curry, J. F., Simons, A. D., & March, J. S. (2008) · Archives of General Psychiatry · doi:10.1001/archpsyc.65.4.447 · Cited by 36
Zhang, M., Fan, C. G., Ma, L., Wang, H., Zu, Z., Lin-xi, Y., Chen, F., Wei, W., & Li, X. (2024) · General Psychiatry · doi:10.1136/gpsych-2023-101355 · Cited by 49
“36 Karyotaki et al 37 employed individual participant data MAs to report the remission and response rates of IBIs for depression.”
Conradi, H. J., Ormel, J., & de Jonge, P. (2012) · Depression and Anxiety · doi:10.1002/da.21960 · Cited by 35
ABCB1 (MDR1) predicts remission on P-gp substrates in chronic depression
Ray, A., Tennakoon, L., Keller, J., Sarginson, J. E., Ryan, H. S., Murphy, G. M., Lazzeroni, L. C., Trivedi, M. H., Kocsis, J. H., DeBattista, C., et al. (2014) · The Pharmacogenomics Journal · doi:10.1038/tpj.2014.72 · Cited by 40
Self-citationShah, A., Carreno, F. R., & Frazer, A. (2014) · Clinical Psychopharmacology and Neuroscience · doi:10.9758/cpn.2014.12.2.83 · Cited by 35
Chu, C.-S., Sun, I.-W., Begum, A., Liu, S., Chang, C., Chiu, W., Chen, C., Tang, H.-S., Yang, C.-L., Lin, Y., et al. (2017) · PLoS ONE · doi:10.1371/journal.pone.0173027 · Cited by 39
“Exploratory stratification was further carried out for higher or lower cognitive function levels (the latter being defined as an MMSE score of 26 or below) [16] and higher or lower current depressive symptoms (the latter being defined as a HDRS score of 6 or below) [37] for those cognitive parameters differing between…”
BackgroundKluczniok, D., Boedeker, K., Attar, C. H., Jaite, C., Bierbaum, A.-L., Fuehrer, D., Paetz, L., Dittrich, K., Herpertz, S. C., Brunner, R. M., et al. (2018) · Journal of Affective Disorders · doi:10.1016/j.jad.2018.02.001 · Cited by 52
Seo, M. K., Lee, J. G., & Park, S. W. (2018) · Neuroscience Letters · doi:10.1016/j.neulet.2018.12.033 · Cited by 40
Marver, J. E., Galfalvy, H., Burke, A. K., Sublette, M. E., Oquendo, M. A., Mann, J. J., & Grunebaum, M. F. (2017) · Suicide and Life-Threatening Behavior · doi:10.1111/sltb.12329 · Cited by 42
Henigsberg, N., Šarac, H., Radoš, M., Radoš, M., Ozretić, D., Foro, T., Turk, V. E., Hrabač, P., Janović, M. B., Rak, B., et al. (2017) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2017.00277 · Cited by 34
“Other antidepressants used by patients who experienced a recurrent episode were sertraline (5), mirtazapine (2), fluoxetine (1), venlafaxine (1), reboxetine (1), citalopram (1), fluvoxamine (1), paroxetine (1), and imipramine (1).”
BackgroundLan, X.-J., Yang, X.-H., Qin, Z.-J., Cai, D.-B., Liu, Q.-M., Mai, J.-X., Deng, C.-J., Huang, X., & Zheng, W. (2023) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2023.1244289 · Cited by 38
Dhingra, S. S., Zack, M. M., Strine, T. W., Druss, B. G., Berry, J. T., & Balluz, L. S. (2011) · Psychiatric Services · doi:10.1176/ps.62.4.pss6204_0396 · Cited by 41
Sackeïm, H. A. (2016) · Brain stimulation · doi:10.1016/j.brs.2016.03.006 · Cited by 32
“Worsening after a remission sustained for six months to a year signified recurrence, and was interpreted as the onset of a new episode of illness [2, 3].”
Self-citationAsp, M., Lindqvist, D., Fernström, J., Ambrus, L., Tuninger, E., Reis, M., & Westrin, Å. (2020) · PLoS ONE · doi:10.1371/journal.pone.0227364 · Cited by 41
“as referring only to the nine criterion symptom domains identified in DSM-IV-TR to diagnose a major depressive disorder [36].”
BackgroundSackeïm, H. A., Roose, S. P., & Lavori, P. W. (2006) · Biological Psychiatry · doi:10.1016/j.biopsych.2005.08.033 · Cited by 33
Self-citationVittengl, J. R., Clark, L. A., & Jarrett, R. B. (2010) · Behaviour Research and Therapy · doi:10.1016/j.brat.2010.01.006 · Cited by 32
“Specifically, our definitions of remission and recovery capture outcomes that arguably are more important to patients and their families because they require a longer duration (Rush et al., 2006), and because few to no symptoms preclude significantly fluctuating and residual symptoms of depression that produce substan…”
BackgroundSternat, T., Fotinos, K., Fine, A., Epstein, I., & Katzman, M. A. (2018) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s170645 · Cited by 39
“The Chi-squared analyses demonstrated that there were significant associations between unrecognized ADHD and number of disorders ( χ 2 [5] = 2 [1] = 5.17, P = 0.023, Φ= 0.231, OR = 5.17) were significantly associated with undetected ADHD in the TRD population.”
InfluentialAdvances in novel molecular targets for antidepressants
Wang, Q., & Dwivedi, Y. (2020) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2020.110041 · Cited by 34
“Despite the availability of a wide range of antidepressants, remission rates in MDD patients are very low (Rush et al., 2006).”
BackgroundZimmerman, M. A., Martinez, J. H., Attiullah, N., Friedman, M. A., Toba, C., & Boerescu, D. A. (2012) · Journal of Affective Disorders · doi:10.1016/j.jad.2012.03.044 · Cited by 37
How emotional abilities modulate the influence of early life stress on hippocampal functioning
Aust, S., Härtwig, E. A., Koelsch, S., Heekeren, H. R., Heuser, I., & Bajbouj, M. (2013) · Social Cognitive and Affective Neuroscience · doi:10.1093/scan/nst078 · Cited by 42
“The cutoff point to exclude subjects with a clinically relevant depressive episode was 12 (Beck et al., 1988; Rush et al., 2006).”
BackgroundEarly relapse (ER) transcranial magnetic stimulation (TMS) in treatment resistant major depression
PRIDMORE, S. A., Erger, S., Rybak, M., Kelly, E., & May, T. (2018) · Brain stimulation · doi:10.1016/j.brs.2018.05.013 · Cited by 34
“When residual symptoms are present in the post-treatment state, relapse is more likely [5,11,12].”
Continuation-phase cognitive therapy's effects on remission and recovery from depression.
Vittengl, J. R., Clark, L. A., & Jarrett, R. B. (2009) · Journal of Consulting and Clinical Psychology · doi:10.1037/a0015238 · Cited by 31
“Marking a higher standard than these traditional definitions, emerging criteria for evaluating treatments emphasize longer periods of minimal or absent depressive symptoms for defining remission (3+ weeks) and especially recovery (4+ months; Rush et al., 2006).”
BackgroundDunn, A. L., & Weintraub, P. (2008) · American Journal of Lifestyle Medicine · doi:10.1177/1559827608323225 · Cited by 32
Llorca, P. (2010) · Journal of Psychopharmacology · doi:10.1177/1359786810372978 · Cited by 33
“…re-evaluated by the American College of Neuropsychopharmacology, which recommended that remission only refer to the nine symptom domains required to diagnose major depressive disorder according to the fourth edition of the Diagnostic and Statistical Manual of Mental Disorder (Rush et al., 2006a).”
BackgroundMethodIsHak, W. W., Greenberg, J. M., Saah, T., Mobaraki, S., Fakhry, H., Wu, Q., Ngor, E., Yu, F., & Cohen, R. M. (2013) · Administration and Policy in Mental Health and Mental Health Services Research · doi:10.1007/s10488-011-0376-6 · Cited by 30
“Depression remission is often defined in terms of symptom resolution, which does not usually (while it should), include consideration of functioning level and quality of life (Rush et al. 2006; Zimmerman et al. 2008).”
BackgroundCoulombe, S., Radziszewski, S., Meunier, S., Provencher, H. L., Hudon, C., Roberge, P., Provencher, M. D., & Houle, J. (2016) · Frontiers in Psychology · doi:10.3389/fpsyg.2016.00584 · Cited by 38
Jha, M. K., Greer, T. L., Grannemann, B. D., Carmody, T. J., Rush, A. J., & Trivedi, M. H. (2016) · Journal of Affective Disorders · doi:10.1016/j.jad.2016.07.012 · Cited by 32
Self-citationRush, A. J., Trivedi, M. H., Wisniewski, S. R., Nierenberg, A. A., Stewart, J. W., Warden, D., Niederehe, G., Thase, M. E., Lavori, P. W., Lebowitz, B. D., et al. (2008) · FOCUS The Journal of Lifelong Learning in Psychiatry · doi:10.1176/foc.6.1.foc128 · Cited by 38
Self-citationShamai‐Leshem, D., Linetzky, M., & Bar‐Haim, Y. (2022) · Cognitive Therapy and Research · doi:10.1007/s10608-022-10331-y · Cited by 36
Judd, L. L., Schettler, P. J., & Rush, A. J. (2016) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2016.15111462 · Cited by 29
Self-citationFriedman, E. S., Wisniewski, S. R., Gilmer, W., Nierenberg, A. A., Rush, A. J., Fava, M., Zisook, S., Balasubramani, G. K., & Trivedi, M. H. (2009) · Depression and Anxiety · doi:10.1002/da.20568 · Cited by 29
Self-citationKolovos, S., Kenter, R. M. F., Bosmans, J. E., Beekman, A. T. F., Cuijpers, P. J., Kok, R. N., & van Straten, A. (2016) · Journal of Affective Disorders · doi:10.1016/j.jad.2016.04.025 · Cited by 27
McClintock, S. M., Brandon, A. R., Husain, M. M., & Jarrett, R. B. (2011) · The Journal of ECT · doi:10.1097/yct.0b013e3181faaeca · Cited by 29
“In addition, prospective research may benefit from the American College of Neuropsychopharmacology (ACNP) Task Force(72) and others’ recommended definitions for response, remission, recovery, relapse, and recurrence.(74,75) Without consensus on these terms, confident interpretation of clinical outcomes is compromised.”
BackgroundD’Avanzato, C., Martinez, J. H., Attiullah, N., Friedman, M., Toba, C., Boerescu, D. A., & Zimmerman, M. A. (2013) · Journal of Affective Disorders · doi:10.1016/j.jad.2013.06.040 · Cited by 38
Steidtmann, D. K., Manber, R., Blasey, C. M., Markowitz, J. C., Klein, D. N., ROTHBAUM, B. O., Thase, M. E., Kocsis, J. H., & Arnow, B. A. (2013) · Journal of Consulting and Clinical Psychology · doi:10.1037/a0033250 · Cited by 29
Self-citationDong, L., Zhao, X., Ong, S. L., & Harvey, A. G. (2017) · Behaviour Research and Therapy · doi:10.1016/j.brat.2017.08.006 · Cited by 30
“Applying criteria from the American College of Neuropsychopharmacology (ACNP) (Rush et al., 2006), response occurred with a decrease of 50% in IDS-SR score from baseline to posttreatment, remission occurred with IDS-SR score of 14 or less at posttreatment, and recurrence was defined as a return to moderate or severe d…”
MethodInfluentialPatient learning of treatment contents in cognitive therapy
Gumport, N. B., Dong, L., Lee, J. Y., & Harvey, A. G. (2017) · Journal of Behavior Therapy and Experimental Psychiatry · doi:10.1016/j.jbtep.2017.08.005 · Cited by 27
Scherf‐Clavel, M., Weber, H., Wurst, C., Stonawski, S., Hommers, L. G., Unterecker, S., Wolf, C., Domschke, K., Rost, N., Brückl, T. M., et al. (2022) · Pharmacopsychiatry · doi:10.1055/a-1872-0613 · Cited by 27
Tao, R., Emslie, G. J., Mayes, T. L., Nakonezny, P. A., & Kennard, B. D. (2010) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2009.0116 · Cited by 28
“A recent task force from the American College of Neuropsychopharmacology (ACNP) recommended a fairly broad definition of response to include individuals who were free of the two core symptoms (sadness and anhedonia) and had up to three of the remaining DSM-IV criterion symptoms (Rush et al. 2006).”
Gili, M., Vicens, C., Roca, M., Andersen, P., & McMillan, D. (2014) · Preventive Medicine · doi:10.1016/j.ypmed.2014.07.035 · Cited by 35
Bosma, H., Lamers, F., Jonkers, C. C. M., & van Eijk, J. T. M. (2011) · Psychiatric Services · doi:10.1176/ps.62.7.pss6207_0793 · Cited by 27
Liu, Y., Zhang, F., Wang, Z., Cao, L., Wang, J., Na, A., Sun, Y., & Zhao, X. (2016) · Psychiatry Research · doi:10.1016/j.psychres.2016.06.029 · Cited by 26
Borza, T., Engedal, K., Bergh, S., Benth, J. Š., & Selbæk, G. (2015) · BMC Psychiatry · doi:10.1186/s12888-015-0577-8 · Cited by 31
“In line with previous recommendations for outcomes in clinical studies of depression [28, 29] and an observational study of DLL using the MADRS, [9], remission was defined by a score of ≤ 9 on the MADRS at the time of discharge.”
MethodResultEbert, D. D., Buntrock, C., Reins, J. A., Zimmermann, J., & Cuijpers, P. J. (2018) · BMJ Open · doi:10.1136/bmjopen-2017-018582 · Cited by 27
“therapy outcome research for depression is a 50% reduction on a standardised depression measure.(89) However, it”
Citrome, L., DiBernardo, A., & Singh, J. (2020) · Journal of Affective Disorders · doi:10.1016/j.jad.2020.03.106 · Cited by 26
Pharmacogenetics of antidepressive treatment
Zobel, A. W., & Maier, W. (2010) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-009-0091-4 · Cited by 26
(2008) · Research at the University of Copenhagen (University of Copenhagen) · Cited by 26
Clinical differences between early and late remission in depressive patients
Roca, M., García-Toro, M., García‐Campayo, J., Vives, M., Armengol, S., García-García, M., Asensio, D., & Gili, M. (2011) · Journal of Affective Disorders · doi:10.1016/j.jad.2011.05.051 · Cited by 30
“The ACNP Task Force on Response and Remission recommends remission as a primary outcome for clinical trials (Rush et al., 2006).”
BackgroundDowlatshahi, E. A., Wakkee, M., Herings, R. M. C., Hollestein, L. M., & Nijsten, T. E. C. (2013) · Acta Dermato Venereologica · doi:10.2340/00015555-1566 · Cited by 26
“According to the American College of Neuropsychopharmacology and other guidelines, recovery from a major depressive episode can be ascribed after at least 4 months of remission have been ascertained (18, 19).”
BackgroundWen, H., Zhu, Z., Hu, T., Li, C., Jiang, T., Li, L., Zhang, L., Fu, Y., Han, S., Wu, B., et al. (2023) · Frontiers in Public Health · doi:10.3389/fpubh.2022.1024436 · Cited by 30
“found that the presence of sadness was associated with a poor prognosis (52).”
BackgroundKushner, S. C., Quilty, L. C., McBride, C., & Bagby, R. M. (2009) · Depression and Anxiety · doi:10.1002/da.20566 · Cited by 24
“First, we lacked information regarding Axis I and Axis II comorbidity, and additional clinical characteristics such as chronicity of depression, prior treatment history, and family psychiatric history.([28]) A commonly cited limit to the generalizability of RCT findings concerns comorbidity: RCTs often exclude individ…”
Background
Metadata
- Authors
- Rush, A. J., Kraemer, H. C., Sackeim, H. A., Fava, M., Trivedi, M. H., Frank, E., Ninan, P. T., Thase, M. E., Gelenberg, A. J., Kupfer, D. J., Regier, D. A., Rosenbaum, J. F., Ray, O., & Schatzberg, A. F.
- Affiliations
- The University of Texas Southwestern Medical Center (US)
- Stanford Medicine (US)
- University of Pittsburgh (US)
- Emory University (US)
- University of Arizona (US)
- American Psychiatric Association (US)
- Harvard University (US)
- Vanderbilt University (US)
- Corresponding author
- Rush, A John
- ORCID
- Venue
- Neuropsychopharmacology
- Published
- 2006-06-21
- Volume
- 31
- Issue
- 9
- Pages
- 1841-1853
- ISSN
- 0893-133X (ISSN-L)
- 1740-634X
- OpenAlex
- W2039979496
- Cited by
- 707
- References
- 132
- Citations by year
- 2026: 22 · 2025: 23 · 2024: 29 · 2023: 58 · 2022: 30 · 2021: 47 · 2020: 30 · 2019: 47 · 2018: 35 · 2017: 30 · 2016: 41 · 2015: 33 · 2014: 32 · 2013: 36 · 2012: 35
- FWCI
- 4.34
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Neuropsychopharmacology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Social Sciences › Psychology › Experimental and Cognitive Psychology › Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes
- Social Sciences › Psychology › Experimental and Cognitive Psychology › Mental Health Research Topics
- Keywords
- major depressive disorder, remission, response, recovery, relapse, recurrence, end points, symptom rating scales, DSM-IV-TR diagnostic criteria, clinical trial results, quality of life
- MeSH terms
- Clinical Trials as Topic, Major Depressive Disorder, Humans, Recurrence, Research Design
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.